15 unknown. 15 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Unknown 15 |
| Phase 1 | 3 | Unknown 3 |
| Phase 3 | 3 | Unknown 3 |
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis TDI01 suspension - Idiopathic Pulmonary Fibrosis | Phase 2 | Unknown | Beijing Tide Pharmaceutical Co., Ltd | 120 | 2023-11-02 | 2023-11-02 |
| Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease. Tofacitinib - Rheumatoid Arthritis, Interstitial Lung Disease | Phase 2 | Unknown | National Institute of Respiratory Diseases, Mexico | 60 | 2022-08-08 | 2023-04-27 |
| Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19 Treamid, Treamid twice a day, Treamid once a day - SARS-CoV-2 Infection, Lung Fibrosis | Phase 2 / Phase 3 | Unknown | PHARMENTERPRISES LLC | 412 | 2022-08-01 | 2022-08-25 |
| A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis AK3280, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Unknown | Shanghai Ark Biopharmaceutical Co., Ltd. | 105 | 2022-07-01 | 2022-07-20 |
| RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF) Cudetaxestat (BLD-0409), Control: Matching Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Unknown | Blade Therapeutics | 200 | 2022-05-31 | 2022-05-18 |
| The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19 MON002 - Pulmonary Fibrosis, Interstitial Lung Disease | Phase 1 / Phase 2 | Unknown | Guy's and St Thomas' NHS Foundation Trust | 5 | 2021-03-08 | 2021-03-18 |
| BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients BIO 300 Oral Suspension, Placebo - COVID-19, Long COVID | Phase 2 | Unknown | Humanetics Corporation | 50 | 2020-11-11 | 2024-10-01 |
| Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients Collagen-Polyvinylpyrrolidone - Covid19, Cytokine Storm | Phase 1 / Phase 2 | Unknown | Janette Furuzawa Carballeda | 90 | 2020-08-19 | 2021-02-17 |
| A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis INOpulse®, Placebo, Long Term Follow Up - Pulmonary Fibrosis, Pulmonary Hypertension | Phase 2 | Unknown | Bellerophon | 85 | 2017-12-29 | 2023-02-28 |
| Feasibility & Effect of a Tele-rehabilitation Program in Idiopathic Pulmonary Fibrosis (IPF) Virtual Autonomous Physiotherapist Agent (VAPA) - Idiopathic Pulmonary Fibrosis | Phase 2 | Unknown | University of Aarhus | 30 | 2017-09-01 | 2018-06-07 |
| Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment Placebo, Pirfenidone - Alveolitis Extrinsic Allergic, Pulmonary Fibrosis | Phase 2 / Phase 3 | Unknown | Grupo Medifarma, S. A. de C. V. | 60 | 2015-07-01 | 2015-07-14 |
| Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis Autologous Stromal Vascular Fraction (SVF), Autologous Adipose Derived MSCs (ADMSCs), Control - Idiopathic Pulmonary Fibrosis | Phase 1 / Phase 2 | Unknown | Kasiak Research Pvt. Ltd. | 60 | 2014-08-01 | 2014-05-13 |
| Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab Bevacizumab, Dexamethasone - Pulmonary Fibrosis | Phase 2 | Unknown | Qingdao Central Hospital | 30 | 2013-08-01 | 2023-03-29 |
| Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF) Pirfenidone, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Unknown | Beijing Kawin Technology Share-Holding Co., Ltd. | 80 | 2012-01-01 | 2012-02-07 |
| Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis Iloprost inhalation - Pulmonary Fibrosis, Pulmonary Hypertension | Phase 2 / Phase 3 | Unknown | Interstitial Lung Disease Study Group, Korea | 15 | 2007-03-01 | 2007-02-23 |
Idiopathic Pulmonary Fibrosis (7) · COVID-19 (4) · Hypertension, Pulmonary (2) · Lung Diseases, Interstitial (2) · Alveolitis, Extrinsic Allergic (1) · Arthritis, Rheumatoid (1) · Cytokine Release Syndrome (1) · Post-Acute COVID-19 Syndrome (1)
Lung Diseases (15) · Respiratory Tract Diseases (15) · Lung Diseases, Interstitial (13) · Fibrosis (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Coronaviridae Infections (4) · Coronavirus Infections (4) · Infections (4) · Nidovirales Infections (4) · Pneumonia (4) · Pneumonia, Viral (4) · RNA Virus Infections (4) · Respiratory Tract Infections (4)
pirfenidone (2) · Bevacizumab (1) · Dexamethasone (1) · Excipients (1) · MON002 (1) · N,N'-bis(2-(1H-imidazol-2-yl)ethyl)pentanediamide (1) · collagen-PVP (1) · tofacitinib (1)
Beijing Kawin Technology Share-Holding Co., Ltd. (1) · Beijing Tide Pharmaceutical Co., Ltd (1) · Bellerophon (1) · Blade Therapeutics (1) · Grupo Medifarma, S. A. de C. V. (1) · Guy's and St Thomas' NHS Foundation Trust (1) · Humanetics Corporation (1) · Interstitial Lung Disease Study Group, Korea (1) · Janette Furuzawa Carballeda (1) · Kasiak Research Pvt. Ltd. (1) · National Institute of Respiratory Diseases, Mexico (1) · PHARMENTERPRISES LLC (1) · Qingdao Central Hospital (1) · Shanghai Ark Biopharmaceutical Co., Ltd. (1) · University of Aarhus (1)
China (3) · Mexico (3) · United States (2) · Denmark (1) · India (1) · South Korea (1) · United Kingdom (1)
Ashika Ahmed, MD (1) · Ashish Patel, PhD FRCS (1) · Bijan Modarai, PhD FRCS (1) · Daniel Azamar-Llamas, MD (1) · Dong Soon Kim, MD (1) · Dr. Ashok A Mahashur, M.B.B.S.M.D. (1) · Dr. Kartik B Shah, M.B.B.S.M.D. (1) · Dr. Pratibha S Singhal, M.B.B.S.M.D. (1) · Dr.Sujeet K Rajan, M.B.B.S.M.D. (1) · Eric Ochoa-Hein, MD (1) · Gonzalo Torres-Villalobos, MD, PhD (1) · Janette Furuzawa-Carballeda, PhD (1) · Jihong Liu (1)
PMID 10415784, PMID 12563677, PMID 14719037, PMID 15663512, PMID 17181919, PMID 18097874, PMID 19397687, PMID 19453649, PMID 19998041, PMID 21131395, PMID 22028728, PMID 22545014, PMID 22731679, PMID 26496265, PMID 26867177, PMID 28584818, PMID 30473697, PMID 31784348, PMID 31986264, PMID 32035018, PMID 32089354, PMID 32113509, PMID 32125455, PMID 32159775, PMID 32192578, PMID 32203186, PMID 32234467, PMID 32257537, PMID 32278362, PMID 32283152, PMID 32360286, PMID 32396163, PMID 33511633, PMID 42722091, PMID 9804346
272201800011C-P00005-9999-1 (1)